---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-011681"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:42:56.431263+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dianthus Therapeutics raises $230M in PIPE financing at $12.00/share

## Summary
- PIPE gross proceeds ~$230M from 14.5M common shares at $12.00 and 4.7M pre-funded warrants at $11.999.
- New and existing investors participating: Bain Capital Life Sciences, RA Capital, Avidity Partners, and others.
- Closing expected Jan 24, 2024; proceeds for R&D, working capital, and potential business development.
- Placement agents: Jefferies, Evercore ISI, Stifel, Guggenheim Securities, Raymond James.

## SEC filing metadata
- accession: 0001193125-24-011681
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312524011681/0001193125-24-011681-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312524011681/d699582d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-011681
- JSON: https://secwatch.observer/filing/0001193125-24-011681.json
- Plain text: https://secwatch.observer/filing/0001193125-24-011681.txt

## Key facts
- Material Agreements
  Dianthus Therapeutics, Inc. /DE/ entered into Registration Rights Agreement with Institutional and accredited investors valued at Registration Rights Agreement for resale registration (effective 2024-01-22).
  - Action: entry
  - Counterparty: Institutional and accredited investors
  - Value: Registration Rights Agreement for resale registration
  - Effective: 2024-01-22
  source text: Also on January 22, 2024, the Company entered into a Registration Rights Agreement (the "Registration Rights Agreement") with the Purchasers, which provides that the Company will register the resale of the Common Shares and the Pre-Funded Warrant Shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312524011681/0001193125-24-011681-index.htm
- Material Agreements
  Dianthus Therapeutics, Inc. /DE/ entered into Securities Purchase Agreement with Institutional and accredited investors valued at 230,000,000 USD (effective 2024-01-22).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Institutional and accredited investors
  - Value: 230,000,000 USD
  - Effective: 2024-01-22
  source text: On January 22, 2024, Dianthus Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a Securities Purchase Agreement (the "Purchase Agreement") for a private placement (the "Private Placement") with certain institutional and accredited investors (each, a "Purchaser" and collectively, the "Purchasers").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312524011681/0001193125-24-011681-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.